Showing results (141-150 of 203) with videos related to

Sort By:
Pageof 21
The Lancet. Oncology|April 4, 2017
Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging systemTamer M Fouad, Angelica M Gutierrez Barrera, James M Reuben, et al.
JAMA Network Open|June 25, 2024
Clinical Outcomes for BRCA Pathogenic Variant Carriers With Breast Cancer Undergoing Breast ConservationKerollos Nashat Wanis, Henry M Kuerer, Susie X Sun, et al.
Practical Radiation Oncology|May 28, 2019
Excellent Locoregional Control in Inflammatory Breast Cancer With a Personalized Radiation Therapy ApproachShane R Stecklein, Kelly J Rosso, Jenny Nuanjing, et al.
Annals of Surgical Oncology|March 4, 2006
Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trialLee Gravatt Wilke, Linda M McCall, Katherine E Posther, et al.
Annals of Surgical Oncology|February 8, 2006
Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsyLaura A Lambert, Gregory D Ayers, Rosa F Hwang, et al.
Breast Cancer Research and Treatment|December 15, 2010
Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancerTakayuki Iwamoto, Giampaolo Bianchini, Yuan Qi, et al.
Annals of Surgical Oncology|July 26, 2019
Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic TherapySusie Sun, Raquel F D van la Parra, Gaiane M Rauch, et al.
The Oncologist|December 8, 2011
Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancerJing Li, Ana M Gonzalez-Angulo, Pamela K Allen, et al.
Springerplus|October 25, 2013
Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinomaSavitri Krishnamurthy, Wendy Woodward, Wei Yang, et al.
Cancer Medicine|December 19, 2019
Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancerNaoto T Ueno, Rie K Tahara, Takeo Fujii, et al.
Pageof 21